---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-062408"
form_type: "8-K"
ticker: null
cik: "0001505512"
company_name: "Regulus Therapeutics Inc."
filed_at: "2025-06-25T23:59:59+00:00"
generated_at: "2026-05-18T19:17:34.668357+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Novartis closes tender offer for Regulus; holders get $7.00 cash plus $7.00 CVR

## Summary
- Tender offer expired June 24 with 74.49% shares tendered; merger completed June 25.
- Shareholders receive $7.00 cash per share plus a CVR that could pay $7.00 if U.S. regulatory approval for ADPKD achieved.
- Regulus stock will be delisted from Nasdaq effective June 25.
- All prior directors and officers removed; replaced by Novartis appointees John McKenna and Eduard Marti.
- Charter and bylaws amended and restated; company becomes Novartis subsidiary.

## SEC filing metadata
- accession: 0001104659-25-062408
- form_type: 8-K
- cik: 0001505512
- company_name: Regulus Therapeutics Inc.
- filed_at: 2025-06-25T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1505512/000110465925062408/0001104659-25-062408-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1505512/000110465925062408/tm2518614d30_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-062408
- JSON: https://secwatch.observer/filing/0001104659-25-062408.json
- Plain text: https://secwatch.observer/filing/0001104659-25-062408.txt

## Key facts
- Governance Changes
  Regulus Therapeutics Inc.: Amended and restated bylaws in connection with merger (effective 2025-06-25).
  - Change: bylaw amendment
  - Effective: 2025-06-25
  source text: Pursuant to the terms of the Merger Agreement, on June 25, 2025, the Company’s certificate of incorporation and bylaws were each amended and restated in their entirety and became the certificate of incorporation and bylaws of the Surviving Corporation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1505512/000110465925062408/0001104659-25-062408-index.htm
- Governance Changes
  Regulus Therapeutics Inc.: Amended and restated certificate of incorporation in connection with merger (effective 2025-06-25).
  - Change: charter amendment
  - Effective: 2025-06-25
  source text: Pursuant to the terms of the Merger Agreement, on June 25, 2025, the Company’s certificate of incorporation and bylaws were each amended and restated in their entirety and became the certificate of incorporation and bylaws of the Surviving Corporation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1505512/000110465925062408/0001104659-25-062408-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.